AMG 827 in Subjects With Psoriatic Arthritis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Psoriatic Arthritis

In brief

The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis

Key facts

Study ID

NCT01516957

Run by

Bausch Health Americas, Inc.

People needed

168

Starts

2011-10-01

Expected to finish

2015-09-01

Last updated by the study team

2020-08-27

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis (CASPAR) criteria) for at least 6 months
• Subject has ≥ 3 tender and ≥ 3 swollen joints

You may not qualify if…

• Subject has an active infection or history of infections (systemic anti-infectives were used within 28 days; requiring hospitalization or intravenous anti-infectives within 8 weeks; recurrent or chronic)
• Significant concurrent medical conditions
• Pregnant or breast feeding
• Significant Laboratory abnormalities
• Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin inhibitors, azathioprine, parenteral corticosteroids including intramuscular or intraarticular administration, or live vaccines within 28 days
• Use of anti-TNF therapy within 2 months
• Use of an anti-interleukin (IL)12/IL-23 drug or other experimental or commercially available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months
• Prior use of rituximab
• Prior use of anti-IL-17 biologic therapy, including AMG 827

Where it is running

• Research Site — Peoria, Arizona, United States
• Research Site — Scottsdale, Arizona, United States
• Research Site — Tucson, Arizona, United States
• Research Site — Hemet, California, United States
• Research Site — Huntington Beach, California, United States
• Research Site — La Jolla, California, United States
• Research Site — Los Angeles, California, United States
• Research Site — Palm Desert, California, United States
• Research Site — Palo Alto, California, United States
• Research Site — Victorville, California, United States
• Research Site — Sarasota, Florida, United States
• Research Site — Boise, Idaho, United States
• Research Site — Lexington, Kentucky, United States
• Research Site — Baton Rouge, Louisiana, United States
• Research Site — Frederick, Maryland, United States
• Research Site — Grand Rapids, Michigan, United States
• Research Site — Lansing, Michigan, United States
• Research Site — Lebanon, New Hampshire, United States
• Research Site — Rochester, New York, United States
• Research Site — Portland, Oregon, United States
• Research Site — Duncansville, Pennsylvania, United States
• Research Site — Seattle, Washington, United States
• Research Site — Victoria, British Columbia, Canada
• Research Site — Winnipeg, Manitoba, Canada
• Research Site — St. John's, Newfoundland and Labrador, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.